Visionary Holdings Partners with Yike Regenerative Medicine to Advance Anti-Aging Biotechnology
Key Insights
Visionary Holdings (search) (NASDAQ: GV) has entered into a strategic partnership with Jiangsu Yike Regenerative Medicine (search) to collaborate on cellular rejuvenation and aesthetic treatment technologies.
The collaboration focuses on three core areas: cell activation and telomerase (search) homeostasis using Yike's proprietary Cell-Activating Complex (search), smart delivery systems with Nano-Delivery™ (search) technology, and stem cell applications.
The partnership is led by Dr. Zhenyu Ju, a renowned aging (search) and regenerative medicine expert from Jinan University (search), who has published extensively in Cell, Nature Genetics, and Nature Medicine.
Visionary Holdings (search) Inc. (NASDAQ: GV) announced on September 17, 2025, a strategic partnership with Jiangsu Yike Regenerative Medicine (search), a leading regenerative medical research institute in China. The collaboration aims to advance research, development, and commercialization in cellular rejuvenation and aesthetic treatment technologies, marking GV's entry into the rapidly expanding consumption healthcare sector.
Partnership Framework and Technology Focus
Under the partnership agreement, Yike will lead project development and fund research activities, with the company filing results and securing related intellectual property upon completion. GV will evaluate outcomes and may acquire or license rights through purchase or leasing agreements, with consideration paid in cash or GV shares.
The collaboration centers on three core technological areas:
Cell Activation and Telomerase (search) Homeostasis: The partnership will build on Yike's proprietary Cell-Activating Complex (search) (CAC) and expertise in telomere (search) detection and intervention to develop advanced anti-aging (search) product lines.
Smart Delivery and Personalized Solutions: The companies will leverage Yike's Nano-Delivery™ (search) ultra-permeable liposomal technology to enhance transdermal absorption of active ingredients, integrated with an AI-based Aging (search) Assessment Model (AAM) for personalized rejuvenation solutions.
Stem Cell and Immune Cell Applications: The collaboration will utilize Yike's experience in stem cell and immune cell therapies through its cGMP-certified laboratories to explore innovative applications in aesthetics and healthcare.
Scientific Leadership and Research Capabilities
The partnership will be guided by Dr. Zhenyu Ju, Chief Scientist of Yike and his research team. Dr. Ju serves as Dean of the Institute of Aging (search) and Regenerative Medicine at Jinan University (search) and is a recipient of China's National Science Fund for Distinguished Young Scholars. He has published extensively in leading journals including Cell, Nature Genetics, and Nature Medicine, and has led multiple national key research programs.
"We are very pleased to collaborate with GV, a company with strong international marking experience and global vision," Dr. Ju commented. "GV's global resources and commercialization experience are highly complementary to Yike's research into aging (search) interventions. This partnership will accelerate the translation of fundamental research into clinical applications, delivering safer and more effective anti-aging solutions to consumers in China and worldwide."
Market Opportunity and Strategic Positioning
The partnership positions both companies to capitalize on the expanding medical aesthetics market. According to industry research cited by GV CEO Jay Lee, China's medical aesthetics market surpassed RMB 200 billion (approximately USD 28 billion) in 2023 and is projected to exceed RMB 500 billion (approximately USD 70 billion) by 2030.
"This partnership with Yike is an essential part of GV's China strategy and a key milestone in our overall development," Lee stated. "The scientific expertise of Dr. Ju's team and Yike's industry capabilities are highly complementary, significantly enhancing our research depth and market presence in aesthetic treatment."
Regional Operations and Commercialization Strategy
GV established Visionary Health Technology Group Limited in Hong Kong in June 2025 as its Asia-Pacific headquarters. Visionary Health will oversee the collaboration and coordinate research, commercialization, and market development efforts across the region. The subsidiary aims to leverage Yike's research capabilities and market resources in mainland China to accelerate technology commercialization and market penetration.
Jiangsu Yike Regenerative Medicine (search) operates as a high-tech enterprise specializing in regenerative medicine and precision anti-aging (search) technologies across multiple platforms, including genetic engineering, stem cell research, and immune cell applications. The company co-established the Institute of Aging and Regenerative Medicine with Jinan University (search) and maintains ISO9001 and cGMP certifications. Its offerings range from genetic and telomere (search) testing to cell therapies and comprehensive health management solutions.